Insightec announced today that it has secured complete Medicare coverage across the U.S. for its MR-guided focused ultrasound treatment of medication-refractory essential tremor.
The coverage comes roughly four years since the Tirat Carmel, Israel–based company won FDA approval for the technology.
Insightec officials said compelling clinical evidence and support from physicians, specialty societies and patients enabled the company to achieve coverage in the final two Medicare jurisdictions. The company has worked closely with the seven Local Medicare Administrative Contractors over the past 18 months.
“Complete Medicare coverage is a significant milestone for Insightec and brings the incisionless treatment option to millions of people,” Dr. Maurice R. Ferré, Insightec’s CEO, said in a news release. “This is the critical next step in our mission to make focused ultrasound a standard of care to improve the lives of people living with a challenging condition.”
Insightec announced in March that it had signed definitive agreements for a $150 million Series F financing round — with a post-money valuation of $1.3 billion.
